Uses of North American Ginseng Fractions for Treating Leukemia
    1.
    发明申请
    Uses of North American Ginseng Fractions for Treating Leukemia 审中-公开
    北美人参用于治疗白血病的用途

    公开(公告)号:US20120263806A1

    公开(公告)日:2012-10-18

    申请号:US13294043

    申请日:2011-11-10

    CPC分类号: A61K36/258

    摘要: The invention is directed to ginseng fractions, methods of preventing or reducing hematological malignancies such as leukemia, and methods of elevating NK cells in a subject by administering to the subject an effective amount of a ginseng fraction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers including food items. The fraction may be made from Panax quinquefolius or may be selected from CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223.

    摘要翻译: 本发明涉及人参级分,预防或减少诸如白血病的血液恶性肿瘤的方法,以及通过向受试者施用有效量的人参级分提高受试者的NK细胞的方法,包含该级分的药物组合物与 另一种药物或一种或多种药学上可接受的载体,包括食品。 该级分可以由Panax quinquefolius制备,或者可以选自CVT-E002,PQ2,PQ223和来自CVT-E002,PQ2和PQ223的纯化级分。

    USES OF NORTH AMERICAN GINSENG FRACTIONS FOR TREATING LEUKEMIA
    2.
    发明申请
    USES OF NORTH AMERICAN GINSENG FRACTIONS FOR TREATING LEUKEMIA 审中-公开
    用于治疗白血病的北美金山分支

    公开(公告)号:US20130243891A1

    公开(公告)日:2013-09-19

    申请号:US13886610

    申请日:2013-05-03

    IPC分类号: A61K36/258

    CPC分类号: A61K36/258 A61K31/715

    摘要: The invention is directed to a method of treating hematological malignancies by administering to the subject ginseng fractions from North American ginseng (Panax quinquefolium). The present invention can be used to activate the proliferation of hemopoietic cells in a patient in need of treatment, or as a therapeutic targeted at conditions characterized by hematological malignancy, such as an abnormal proliferation of blood cells, lymphocytes, multiple myeloma, etc. The invention also includes a method of treating leukemia by activating the proliferation of natural killer (NK) cells and monocytes in the bone marrow and the spleen of the patient by administering at least one ginseng fraction selected from the group consisting of CVT-E002, PQ.sub.2, PQ.sub.223 and purified fractions from CVT-E002, PQ.sub.2 and PQ.sub.223. The present invention may be used to treat the hematological malignancy or as a supplement for patients undergoing chemotherapy or radiation therapy.

    摘要翻译: 本发明涉及通过对来自北美人参(Panax quinquefolium)的受试者的人参成分施用治疗血液恶性肿瘤的方法。 本发明可用于激活需要治疗的患者中造血细胞的增殖,或用作以血液恶性肿瘤为特征的病症,如血细胞,淋巴细胞,多发性骨髓瘤等的异常增殖。 本发明还包括通过施用至少一种选自CVT-E002,PQ的人参组分来激活骨髓和患者的脾脏中的天然杀伤(NK)细胞和单核细胞的增殖来治疗白血病的方法。 sub.2,PQ2.23和来自CVT-E002,PQ2和PQ2.23的纯化级分。 本发明可用于治疗血液恶性肿瘤或作为进行化疗或放射治疗的患者的补充。

    USES OF NORTH AMERICAN GINSENG FRACTIONS FOR TREATING LEUKEMIA
    4.
    发明申请
    USES OF NORTH AMERICAN GINSENG FRACTIONS FOR TREATING LEUKEMIA 审中-公开
    用于治疗白血病的北美金山分支

    公开(公告)号:US20100260871A1

    公开(公告)日:2010-10-14

    申请号:US12600301

    申请日:2007-05-16

    IPC分类号: A61K36/258 A61P35/02

    CPC分类号: A61K36/258 A61K31/715

    摘要: The invention is directed to a method of treating hematological malignancies by administering to the subject ginseng fractions from North American ginseng (Panax quinquefolium). The present invention can be used to activate the proliferation of hemopoietic cells in a patient in need of treatment, or as a therapeutic targeted at conditions characterized by hematological malignancy, such as an abnormal proliferation of blood cells, lymphocytes, multiple myeloma, etc. The invention also includes a method of treating leukemia by activating the proliferation of natural killer (NK) cells and monocytes in the bone marrow and the spleen of the patient by administering at least one ginseng fraction selected from the group consisting of CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223. The present invention may be used to treat the hematological malignancy or as a supplement for patients undergoing chemotherapy or radiation therapy.

    摘要翻译: 本发明涉及通过对来自北美人参(Panax quinquefolium)的受试者的人参成分施用治疗血液恶性肿瘤的方法。 本发明可用于激活需要治疗的患者中造血细胞的增殖,或用作以血液恶性肿瘤为特征的病症,如血细胞,淋巴细胞,多发性骨髓瘤等的异常增殖。 本发明还包括通过施用至少一种选自CVT-E002,PQ2,...的人参组分来激活患者的骨髓和脾脏中的天然杀伤(NK)细胞和单核细胞的增殖来治疗白血病的方法, PQ223和来自CVT-E002,PQ2和PQ223的纯化级分。 本发明可用于治疗血液恶性肿瘤或作为进行化疗或放射治疗的患者的补充。

    N.sup.1 -propargylhydrazines, N.sup.2 -propargylhydrazines and their
analogs for the treatment of depression, anxiety and neurodegeneration
    7.
    发明授权
    N.sup.1 -propargylhydrazines, N.sup.2 -propargylhydrazines and their analogs for the treatment of depression, anxiety and neurodegeneration 失效
    N1炔丙基肼,N2-炔丙基肼及其类似物用于治疗抑郁症,焦虑和神经退行性疾病

    公开(公告)号:US6060516A

    公开(公告)日:2000-05-09

    申请号:US024113

    申请日:1998-02-17

    IPC分类号: A61R31/045

    CPC分类号: C07C243/18

    摘要: The present invention is directed to novel N.sup.1 -propargylhydrazines, N.sup.2 -propargylhydrazines and their salts in pharmaceutical compositions. The compounds according to the present invention have at least one of the following activities: monoamine oxidase-A inhibiting, monoamine oxidase-B inhibiting, anti-depressant, anti-anxiety and neuroprotectant activities. These compounds are useful as monoamine oxidase inhibitors and should be useful for the treatment of depression, anxiety and of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

    摘要翻译: 本发明涉及新的N-炔丙基肼,其在药物组合物中的N-炔丙基肼及其盐。 根据本发明的化合物具有以下活性中的至少一种:单胺氧化酶-A抑制,单胺氧化酶-B抑制,抗抑郁,抗焦虑和神经保护作用。 这些化合物可用作单胺氧化酶抑制剂,并且可用于治疗抑郁症,焦虑症和神经变性疾病如帕金森病和阿尔茨海默病。

    USE OF GINSENG FRACTIONS FOR PREVENTING OR REDUCING HEMATOLOGICAL MALIGNANCIES
    10.
    发明申请
    USE OF GINSENG FRACTIONS FOR PREVENTING OR REDUCING HEMATOLOGICAL MALIGNANCIES 审中-公开
    用于预防或减少血液恶性肿瘤的金山分子

    公开(公告)号:US20100221365A1

    公开(公告)日:2010-09-02

    申请号:US12394313

    申请日:2009-02-27

    IPC分类号: A61K36/258 A61P7/00 A61P35/02

    CPC分类号: A61K36/258

    摘要: The invention is directed to ginseng fractions, methods of preventing or reducing hematological malignancies such as leukemia, and methods of elevating NK cells in a subject by administering to the subject an effective amount of a ginseng fraction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers including food items. The fraction may be made from Panax quinquefolius or may be selected from CVT-E002, PQ2, PQ223 and purified fractions from CVT-E002, PQ2 and PQ223.

    摘要翻译: 本发明涉及人参级分,预防或减少诸如白血病的血液恶性肿瘤的方法,以及通过向受试者施用有效量的人参级分提高受试者的NK细胞的方法,包含该级分的药物组合物与 另一种药物或一种或多种药学上可接受的载体,包括食品。 该级分可以由Panax quinquefolius制备,或者可以选自CVT-E002,PQ2,PQ223和来自CVT-E002,PQ2和PQ223的纯化级分。